Significant & Growing Market Opportunity

Global pharma rapidly shifting to precision medicine  to target better patient care, capture lost  revenue and increase profitability.

Strong Competitive Advantage

3 Unique assets

  • Global network of labs
  • World’s largest repository of healthcare data
  • DXRX platform - well invested & scalable

Compelling Value Proposition

  • For pharma, labs, physicians & patients
  • Platform can deliver up to $100 in additional therapy revenue for every $1 invested via DXRX
  • Value throughout the drug life-cycle

Financial Strength

  • High margins
  • Recurring revenue driving order book visibility
  • Blue-chip customers
  • 3-year revenue CAGR of 25%
  • Fully self-funded to execute growth plans
  • Enterprise-wide deals will drive momentum

Demonstrable Track Record

  • Experts in PM & diagnostic commercialisation
  • Proven track record of successful execution, performance & growth
  • Embedded & trusted Precision Medicine partner to 18 of top 20 global pharma

DXRX

First to Market

DXRX is a unique diagnostics commercialisation platform for Precision medicine that addresses the issues. 

It allows stakeholders in the Precision Medicine diagnostics market to collaborate and shape the marketplace, in real time.  It reduces the diagnostic hurdles ensuring that laboratories globally are test ready for each new Precision Medicine at launch. This significantly increases pharma’s Return on Investment on developing new drugs.

Ultimately, we help physicians deliver the right medicine to each individual patient in relation to their own personal pathology.

DXRX

The world’s richest repository of real-world diagnostic testing data

Through the delivery of our consulting services to overcome the hurdles to successful Precision Medicine diagnostics, we have gathered the world’s largest repository of real-world testing data and developed unique insights into the successful commercialisation of Precision Medicine diagnostics, to create a comprehensive and unique offering, accessible via the subscription model.

The more projects we complete the more exhaust data we have to differentiate our platform and generate revenue.

Diaceutics PLC

Nick Roberts
Chief Financial Officer



Nominated adviser and broker

Cannacord Genuity Limited
88 Wood Street
London
EC2V 8AF


Media Contacts 

Alma PR
71-73 Carter Lane
London
EC4V 5EQ

Tel: +44 (0)20 3405 0205 or [email protected]



 
Caroline Forde

 
Kieran Breheny